PACB 10-Q: SEC filing

Pacific Biosciences

Filed with the SEC on · accession 0001299130-26-000138

PACB filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. Pacific Biosciences filed its quarterly report on Form 10-Q for the period ending Q3 2026, with CEO Mark Van Oene certifying the financial statements under Sarbanes-Oxley Section 302. The stock moved -4.7% by the first close after the filing.

Summary of the filing

Pacific Biosciences filed its quarterly report on Form 10-Q for the period ending Q3 2026, with CEO Mark Van Oene certifying the financial statements under Sarbanes-Oxley Section 302. Van Oene is also serving as interim Chief Financial Officer.

Key details

RegistrantPacific Biosciences of California, Inc.
President, chief executive officer and interim chief financial officerMark Van Oene

How PACB stock reacted

Close before

$2.55

Nov 4, 2026

First close after

-4.71%

$2.43

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for PACB, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for PACB?

Click here

Frequently asked questions

What did PACB file with the SEC on Nov 5, 2026?

PACB filed a 10-Q (SEC filing). Pacific Biosciences filed its quarterly report on Form 10-Q for the period ending Q3 2026, with CEO Mark Van Oene certifying the financial statements under Sarbanes-Oxley Section 302. Van Oene is also serving as interim Chief Financial Officer.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

How did PACB stock react to this filing?

PACB closed at $2.55 before the filing and $2.43 on Nov 5, 2026 (-4.71%).

Other PACB SEC filings

Get alerts when PACB files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days